Dyslipidemia – Epidemiology – Emerging Markets Data

  • The total number of prevalent cases of primary prevention dyslipidemia in the countries under study will increase by 10%, from 1.3 billion in 2016 to 1.4 billion in 2026.
  • The total number of prevalent cases of secondary prevention dyslipidemia in the countries under study will increase by 21%, from 305 million in 2016 to 370 million in 2026.
  • Elevated LDL-cholesterol is the most common form of dyslipidemia among non-drug-treated persons in the countries under study.

Table of contents

  • Dyslipidemia - Epidemiology - Emerging Markets Data
    • Introduction
      • Key Findings
        • Overview
          • Prevalence of Primary Prevention Dyslipidemia per 1,000 People Aged 20+ in 2016 and 2026
          • Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Primary Prevention Dyslipidemia over the Next Ten Years
          • Prevalence of Secondary Prevention Dyslipidemia per 1,000 People Aged 20+ in 2016 and 2026
          • Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Secondary Prevention Dyslipidemia over the Next Ten Years
      • Epidemiology Data
      • Methods
        • Total Prevalent Cases of Dyslipidemia
        • Total Prevalent Cases of Primary and Secondary Prevention
      • Reference Materials
        • Primary and Secondary Dyslipidemia Disease Definition
          • Literature Review
            • Studies Included in the Analysis of Dyslipidemia
            • Studies Excluded from the Analysis of Dyslipidemia
          • Risk/Protective Factors
            • Risk/Protective Factors for Dyslipidemia
          • Bibliography